Retrograde Intrarenal Surgery (RIRS) With High-Power Laser and Flexible, Navigable Suction Access Sheath (FANS) vs Mini-Percutaneous Nephrolithotomy (miniPCNL) for 2-3 cm Renal Stones
Flexible Ureterorenoscopy With High-Power Holmium: YAG Laser and Flexible, Navigable Suction Access Sheath vs Mini-Percutaneous Nephrolithotomy in 2-3 cm Kidney Stones Treatment: A Prospective Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Konya
-
Konya, Konya, Turkey (Türkiye)
- Necmettin Erbakan University Medical Faculty
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years
- Kidney stones measuring 2-3 cm
- Suitable for Retrograde Intrarenal Surgery (RIRS) or Mini-Percutaneous Nephrolithotomy (MiniPCNL)
- Provided written informed consent
Exclusion Criteria:
- Pregnancy
- Renal transplantation
- Congenital renal anomalies
- Uncorrectable coagulopathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Retrograde Intrarenal Surgery (RIRS) Group
Intervention: Procedure-Retrograde Intrarenal Surgery
|
We performed retrograde intrarenal surgery combined with a high-power Holmium:YAG laser and flexible navigable suction access sheath in patients with 2-3 cm renal stones.
|
|
Experimental: Mini-Percutaneous Nephrolithotomy (MiniPCNL) Group
Intervention: Procedure- Mini Percutaneous Nephrolithotomy
|
We performed mini-percutaneous nephrolithotomy in patients with 2-3 cm renal stones.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Stone-Free Rate
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Hemoglobin change
Time Frame: postoperative first day
|
postoperative first day
|
|
Fluoroscopy time
Time Frame: Perioperative
|
Perioperative
|
|
Complications
Time Frame: up to 4 weeks
|
up to 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Calculi
- Pathological Conditions, Anatomical
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urolithiasis
- Urinary Calculi
- Pathological Conditions, Signs and Symptoms
- Kidney Calculi
- Nephrolithiasis
Other Study ID Numbers
Other Study ID Numbers
- RIRS-MiniPCNL-2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.